Cyrano Therapeutics has successfully closed a $12.8M Series A round in November 2020 led by Remiges Ventures and Lumira Ventures. The funds will be used to complete a Phase 2 clinical trial of the company’s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company’s board of directors.
Based in Seattle and Tokyo, Remiges Ventures is a US-Japan cross-border venture capital firm focused on therapeutics. Remiges Ventures takes a lead position for the syndication of Series A or later stage investment rounds globally and actively creates new companies based on innovative assets discovered at Japanese academic institutions. Remiges Ventures’ team is connected with serial entrepreneurs, KOLs in various therapeutic areas, key consultants and major large pharmaceutical companies around the globe. The team actively participates in the value creation of its portfolio companies.
Lumira executes a consistent, proven investment strategy as a lead investor and active partner with our portfolio companies. We focus on companies whose products offer transformative (not incremental) improvements to patient health outcomes, and the promise of dramatic reductions in the cost of healthcare delivery. Our Canadian heritage helps us “skate to where the puck is going to be,” investing in the new science and clinical insights that we expect will be driving the next decade of patient care.